Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Simon Crumpler is active.

Publication


Featured researches published by Simon Crumpler.


Journal of Biological Chemistry | 2010

Structural Basis of Poly(Adp-Ribose) Recognition by the Multizinc Binding Domain of Checkpoint with Forkhead-Associated and Ring Domains (Chfr).

Jasmeen Oberoi; Mark W. Richards; Simon Crumpler; Nathan Brown; Julian Blagg; Richard Bayliss

Cellular stress in early mitosis activates the antephase checkpoint, resulting in the decondensation of chromosomes and delayed mitotic progression. Checkpoint with forkhead-associated and RING domains (CHFR) is central to this checkpoint, and its activity is ablated in many tumors and cancer cell lines through promoter hypermethylation or mutation. The interaction between the PAR-binding zinc finger (PBZ) of CHFR and poly(ADP-ribose) (PAR) is crucial for a functional antephase checkpoint. We determined the crystal structure of the cysteine-rich region of human CHFR (amino acids 425–664) to 1.9 Å resolution, which revealed a multizinc binding domain of elaborate topology within which the PBZ is embedded. The PBZ of CHFR closely resembles the analogous motifs from aprataxin-like factor and CG1218-PA, which lie within unstructured regions of their respective proteins. Based on co-crystal structures of CHFR bound to several different PAR-like ligands (adenosine 5′-diphosphoribose, adenosine monophosphate, and P1P2-diadenosine 5′-pyrophosphate), we made a model of the CHFR-PAR interaction, which we validated using site-specific mutagenesis and surface plasmon resonance. The PBZ motif of CHFR recognizes two adenine-containing subunits of PAR and the phosphate backbone that connects them. More generally, PBZ motifs may recognize different numbers of PAR subunits as required to carry out their functions.


Journal of Medicinal Chemistry | 2013

Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-B]Pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells.

Vassilios Bavetsias; Amir Faisal; Simon Crumpler; Nathan Brown; Magda N. Kosmopoulou; Amar Joshi; Butrus Atrash; Yolanda Pérez-Fuertes; Jessica Schmitt; Katherine J. Boxall; Rosemary Burke; Chongbo Sun; Sian Avery; Katherine Bush; Alan T. Henley; Florence I. Raynaud; Paul Workman; Richard Bayliss; Spiros Linardopoulos; Julian Blagg

Aurora-A differs from Aurora-B/C at three positions in the ATP-binding pocket (L215, T217, and R220). Exploiting these differences, crystal structures of ligand–Aurora protein interactions formed the basis of a design principle for imidazo[4,5-b]pyridine-derived Aurora-A-selective inhibitors. Guided by a computational modeling approach, appropriate C7-imidazo[4,5-b]pyridine derivatization led to the discovery of highly selective inhibitors, such as compound 28c, of Aurora-A over Aurora-B. In HCT116 human colon carcinoma cells, 28c and 40f inhibited the Aurora-A L215R and R220K mutants with IC50 values similar to those seen for the Aurora-A wild type. However, the Aurora-A T217E mutant was significantly less sensitive to inhibition by 28c and 40f compared to the Aurora-A wild type, suggesting that the T217 residue plays a critical role in governing the observed isoform selectivity for Aurora-A inhibition. These compounds are useful small-molecule chemical tools to further explore the function of Aurora-A in cells.


Journal of Medicinal Chemistry | 2015

Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen

Aurélie Mallinger; Simon Crumpler; Mark Pichowicz; Dennis Waalboer; Mark Stubbs; Olajumoke Adeniji-Popoola; Bozena Wood; Elizabeth L. Smith; Ching Thai; Alan T. Henley; Katrin Georgi; William Court; Steve Hobbs; Gary Box; Maria-Jesus Ortiz-Ruiz; Melanie Valenti; Alexis de Haven Brandon; Robert TePoele; Birgitta Leuthner; Paul Workman; Wynne Aherne; Oliver Poeschke; Trevor Clive Dale; Dirk Wienke; Christina Esdar; Felix Rohdich; Florence I. Raynaud; Paul A. Clarke; Suzanne A. Eccles; Frank Stieber

WNT signaling is frequently deregulated in malignancy, particularly in colon cancer, and plays a key role in the generation and maintenance of cancer stem cells. We report the discovery and optimization of a 3,4,5-trisubstituted pyridine 9 using a high-throughput cell-based reporter assay of WNT pathway activity. We demonstrate a twisted conformation about the pyridine–piperidine bond of 9 by small-molecule X-ray crystallography. Medicinal chemistry optimization to maintain this twisted conformation, cognisant of physicochemical properties likely to maintain good cell permeability, led to 74 (CCT251545), a potent small-molecule inhibitor of WNT signaling with good oral pharmacokinetics. We demonstrate inhibition of WNT pathway activity in a solid human tumor xenograft model with evidence for tumor growth inhibition following oral dosing. This work provides a successful example of hypothesis-driven medicinal chemistry optimization from a singleton hit against a cell-based pathway assay without knowledge of the biochemical target.


Journal of Medicinal Chemistry | 2012

Optimization of Imidazo[4,5-B]Pyridine-Based Kinase Inhibitors: Identification of a Dual Flt3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia.

Vassilios Bavetsias; Simon Crumpler; Chongbo Sun; Sian Avery; Butrus Atrash; Amir Faisal; Andrew S. Moore; Magda N. Kosmopoulou; Nathan Brown; Peter Sheldrake; Katherine Bush; Alan T. Henley; Gary Box; Melanie Valenti; Alexis de Haven Brandon; Florence I. Raynaud; Paul Workman; Suzanne A. Eccles; Richard Bayliss; Spiros Linardopoulos; Julian Blagg

Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A Kd = 7.5 nM, Aurora-B Kd = 48 nM), FLT3 kinase (Kd = 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd = 38 nM) and FLT3(D835Y) (Kd = 14 nM). FLT3-ITD causes constitutive FLT3 kinase activation and is detected in 20–35% of adults and 15% of children with acute myeloid leukemia (AML), conferring a poor prognosis in both age groups. In an in vivo setting, 27e strongly inhibited the growth of a FLT3-ITD-positive AML human tumor xenograft (MV4–11) following oral administration, with in vivo biomarker modulation and plasma free drug exposures consistent with dual FLT3 and Aurora kinase inhibition. Compound 27e, an orally bioavailable dual FLT3 and Aurora kinase inhibitor, was selected as a preclinical development candidate for the treatment of human malignancies, in particular AML, in adults and children.


Journal of Medicinal Chemistry | 2016

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

Aurélie Mallinger; Kai Schiemann; Christian Rink; Frank Stieber; Michel Calderini; Simon Crumpler; Mark Stubbs; Olajumoke Adeniji-Popoola; Oliver Poeschke; Michael Busch; Paul Czodrowski; Djordje Musil; Daniel Schwarz; Maria-Jesus Ortiz-Ruiz; Richard Schneider; Ching Thai; Melanie Valenti; Alexis de Haven Brandon; Rosemary Burke; Paul Workman; Trevor Clive Dale; Dirk Wienke; Paul A. Clarke; Christina Esdar; Florence I. Raynaud; Suzanne A. Eccles; Felix Rohdich; Julian Blagg

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.


Cancer Research | 2016

Abstract 3025: Discovery of preclinical development candidate inhibitors of the mediator complex-associated kinases CDK8 and CDK19 and evaluation of their therapeutic potential

Paul A. Clarke; Christina Esdar; Aurélie Mallinger; Kai Schiemann; Dennis Waalboer; Simon Crumpler; Christian Rink; Frank Stieber; Michel Calderini; Olajumoke Adeniji-Popoola; Maria-Jesus Ortiz-Ruiz; Rahul S. Samant; Paul Czodrowski; Djordje Musil; Daniel Schwarz; Klaus Schneider; Michael Busch; Mark Stubbs; Rosemary Burke; Robert TePoele; Sharon Gowan; Felix Rohdich; Florence I. Raynaud; Richard Schneider; Oliver Poeschke; Andree Blaukat; Klaus Urbahns; Paul Workman; Wolfgang Kaufmann; Stephanie Simon

Background The Mediator complex-associated kinases CDK8 and CDK19 are cyclin C-dependent enzymes that, with MED12 and MED13, form the kinase module of the Mediator complex. CDK8 expression correlates with activation of β-catenin in colon and gastric cancers and has also been associated with increased mortality in colorectal, breast and ovarian cancers. CDK8 is located in a region of chromosome 13 known to undergo copy number gain in ∼60% of colorectal cancers and inducible shRNA-mediated knockdown of CDK8 protein reduces the growth of colorectal cancer human tumor xenograft animal models harboring CDK8 gene amplification. Results Here we report the discovery and evaluation of CCT251545, a potent, selective and orally bioavailable small molecule chemical probe for CDK8 and CDK19 that we identified from a cell-based WNT pathway screen [1]. We also report a structure-based design approach to the discovery of CCT251921, a potent, selective and orally bioavailable inhibitor of CDK8, with equipotent affinity for CDK19, that has optimised pharmacokinetic and pharmaceutical properties suitable for preclinical development. Furthermore, we describe the discovery of MSC2530818, a structurally differentiated back-up candidate with equivalent pharmacological profile to CCT251921, from a high throughput screen versus CDK8 and subsequent structure-based design. Taking advantage of these two structurally distinct and highly selective dual CDK8/19 modulators we were able to reliably define on-target effects of targeting both CDK8 and CDK19 in the cellular context and in in vivo animal models. We describe gene expression profiles resulting from dual inhibition of CDK8 and CDK19 to demonstrate robust modulation of WNT signalling and additional pathways, including stress and immune response, consistent with the multiple contexts in which Mediator complex is known to regulate gene transcription. We show that both CCT251921 and MSC2530818 exhibit potent cell-based and in vivo inhibition of STAT1SER727 phosphorylation, a target engagement biomarker of CDK8 inhibition, and further demonstrate in vivo antiproliferative activity in human tumour xenograft animal models of colorectal cancer and acute myeloid leukaemia at exposures where pharmacodynamics biomarker modulation is evident. Recent observations suggest CDK8 as a novel anticancer therapeutic target; here we will disclose, for the first time, comprehensive preclinical efficacy, toleration and safety findings for both CCT251921 and MSC2530818 which will inform on the potential for dual CDK8/19 inhibition in the clinical setting. References 1. Dale, T. et. al. Identification of a potent and selective chemical probe for exploring the role of Mediator complex-associated protein kinases CDK8 and CDK19 in human disease. 2015, Nat. Chem. Biol., 11, 973-980. Citation Format: Paul Clarke, Christina Esdar, Aurelie Mallinger, Kai Schiemann, Dennis Waalboer, Simon Crumpler, Christian Rink, Frank Stieber, Michel Calderini, Olajumoke Adeniji-Popoola, Maria-Jesus Ortiz-Ruiz, Rahul S. Samant, Paul Czodrowski, Djordje Musil, Daniel Schwarz, Klaus Schneider, Michael Busch, Mark Stubbs, Rosemary Burke, Robert TePoele, Sharon Gowan, Felix Rohdich, Florence Raynaud, Richard Schneider, Oliver Poeschke, Andree Blaukat, Klaus Urbahns, Paul Workman, Wolfgang Kaufmann, Stephanie Simon, Suzanne A. Eccles, Trevor Dale, Dirk Wienke, Julian Blagg. Discovery of preclinical development candidate inhibitors of the mediator complex-associated kinases CDK8 and CDK19 and evaluation of their therapeutic potential. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3025.


Archive | 2009

Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer

Edward McDonald; Julian Blagg; Mark Pichowicz; Simon Crumpler


Tetrahedron | 2010

Microwave-assisted synthesis of 4-amino-3,5-dihalopyridines

Mark Pichowicz; Simon Crumpler; Edward McDonald; Julian Blagg


Archive | 2015

COMPUESTOS DE 2-AMINOPIRIDINA

Simon Crumpler; Frank Stieber; Julian Blagg; Aurélie Mallinger; Christian Rink; Dennis Waalboer; Kai Schiemann


Archive | 2013

Aurora Isoform Selectivity: Design and Synthesis of Imidazo [4, 5-b] pyridine Derivatives as Highly

Vassilios Bavetsias; Amir Faisal; Simon Crumpler; Nathan Brown; Magda N. Kosmopoulou; Amar Joshi; Butrus Atrash; Yolanda Pérez-Fuertes; Jessica Schmitt; Katherine J. Boxall

Collaboration


Dive into the Simon Crumpler's collaboration.

Top Co-Authors

Avatar

Nathan Brown

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Florence I. Raynaud

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Mark Pichowicz

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Paul Workman

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Amir Faisal

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Aurélie Mallinger

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Butrus Atrash

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Edward McDonald

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Magda N. Kosmopoulou

Institute of Cancer Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge